دورية أكاديمية
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
| العنوان: | CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. |
|---|---|
| المؤلفون: | Komdeur FL; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Wouters MC; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, The Netherlands., Workel HH; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Tijans AM; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Terwindt AL; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Brunekreeft KL; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Plat A; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Klip HG; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Eggink FA; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Leffers N; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Helfrich W; University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands., Samplonius DF; University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands., Bremer E; University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands., Wisman GB; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., Daemen T; University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, The Netherlands., Duiker EW; University of Groningen, University Medical Center Groningen, Department of Pathology, The Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, The Netherlands., Nijman HW; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands., de Bruyn M; University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands. |
| المصدر: | Oncotarget [Oncotarget] 2016 Nov 15; Vol. 7 (46), pp. 75130-75144. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مواضيع طبية MeSH: | CD8-Positive T-Lymphocytes* , Lymphocytes, Tumor-Infiltrating*, Antigens, CD/*metabolism , Integrin alpha Chains/*metabolism , Intraepithelial Lymphocytes/*immunology , Intraepithelial Lymphocytes/*metabolism , Ovarian Neoplasms/*immunology , Ovarian Neoplasms/*metabolism , Receptors, Antigen, T-Cell, alpha-beta/*metabolism, Biomarkers ; Female ; Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Neoplasm Grading ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Phenotype ; Prognosis ; Programmed Cell Death 1 Receptor/metabolism ; Protein Serine-Threonine Kinases/metabolism ; Receptor, Transforming Growth Factor-beta Type I ; Receptors, Transforming Growth Factor beta/metabolism ; Signal Transduction ; Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism |
| مستخلص: | CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific epithelial infiltration and a prolonged survival in high-grade serous epithelial ovarian cancer (HGSC). However, whether these cells are induced as part of an ongoing anti-HGSC immune response or represent non-specifically expanded resident or mucosal lymphocytes remains largely unknown. In this study, we first confirmed that CD103+ TIL from HGSC were predominantly localized in the cancer epithelium and were strongly correlated with an improved prognosis. We further demonstrate that CD103+ TIL were almost exclusively CD3+ TCRαβ+ CD8αβ+ CD4- T cells, but heterogeneously expressed T cell memory and differentiation markers. Activation of peripheral T cells in the presence of HGSC was sufficient to trigger induction of CD103 in over 90% of all CD8+ cells in a T cell receptor (TCR)- and TGFβR1-dependent manner. Finally, CD103+ TIL isolated from primary HGSC showed signs of recent activation and dominantly co-expressed key immunotherapeutic targets PD-1 and CD27. Taken together, our data indicate CD103+ TIL in HGSC are formed as the result of an adaptive anti-tumor immune response that might be reactivated by (dual) checkpoint inhibition. |
| References: | J Immunol. 2015 Apr 1;194(7):3475-86. (PMID: 25725111) Nat Immunol. 2013 Dec;14(12):1294-301. (PMID: 24162776) J Exp Med. 2007 Mar 19;204(3):559-70. (PMID: 17325197) Cancer Res. 2009 Aug 1;69(15):6249-55. (PMID: 19638592) Sci Rep. 2015 Oct 06;5:14495. (PMID: 26440065) J Immunother. 2011 Jul-Aug;34(6):516-23. (PMID: 21654520) Clin Cancer Res. 2014 Jan 1;20(1):44-55. (PMID: 24045181) Immunity. 2014 Oct 16;41(4):633-45. (PMID: 25308332) Clin Cancer Res. 2016 Jun 15;22(12):3025-36. (PMID: 27306793) Cancer Res. 2013 Jan 15;73(2):617-28. (PMID: 23188505) Cancer Res. 2016 Apr 1;76(7):1757-69. (PMID: 26921343) J Immunol. 2014 Mar 1;192(5):2471-9. (PMID: 24477908) J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210. (PMID: 7834119) Cancer Res. 2011 Jan 15;71(2):328-38. (PMID: 21224355) J Transl Med. 2013 Feb 12;11:37. (PMID: 23402380) CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. (PMID: 20610543) Clin Cancer Res. 2016 Feb 1;22(3):714-24. (PMID: 26384738) J Natl Cancer Inst. 2014 Apr 03;106(5):null. (PMID: 24700803) Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6175-80. (PMID: 22474352) J Immunol. 2005 Oct 1;175(7):4355-62. (PMID: 16177076) Int J Gynecol Cancer. 2016 May;26(4):671-9. (PMID: 26905331) Cancer Immunol Res. 2015 Aug;3(8):926-35. (PMID: 25957117) Eur J Cancer. 2016 Jun;60:1-11. (PMID: 27038842) Nat Immunol. 2011 Jun;12(6):485-91. (PMID: 21739671) J Clin Invest. 2014 May;124(5):2246-59. (PMID: 24667641) Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15. (PMID: 17062687) Cancer Immunol Immunother. 2009 Mar;58(3):449-59. (PMID: 18791714) Clin Cancer Res. 2014 Jan 15;20(2):434-44. (PMID: 24190978) Gynecol Oncol. 2012 Feb;124(2):192-8. (PMID: 22040834) Nat Rev Cancer. 2011 Sep 23;11(10):719-25. (PMID: 21941283) Cell. 2000 Oct 13;103(2):295-309. (PMID: 11057902) Nat Med. 2014 Jun;20(6):607-15. (PMID: 24793239) Front Immunol. 2015 Oct 12;6:500. (PMID: 26528284) Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. (PMID: 16344461) Nat Immunol. 2011 Apr;12(4):312-9. (PMID: 21297643) J Urol. 2015 Aug;194(2):556-62. (PMID: 25752441) |
| فهرسة مساهمة: | Keywords: CD103; TGF-β; cancer immunotherapy; high-grade serous ovarian cancer; tumor-infiltrating lymphocytes |
| المشرفين على المادة: | 0 (Antigens, CD) 0 (Biomarkers) 0 (Integrin alpha Chains) 0 (PDCD1 protein, human) 0 (Programmed Cell Death 1 Receptor) 0 (Receptors, Antigen, T-Cell, alpha-beta) 0 (Receptors, Transforming Growth Factor beta) 0 (Tumor Necrosis Factor Receptor Superfamily, Member 7) 0 (alpha E integrins) EC 2.7.11.1 (Protein Serine-Threonine Kinases) EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I) |
| تواريخ الأحداث: | Date Created: 20160922 Date Completed: 20180226 Latest Revision: 20211204 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC5342728 |
| DOI: | 10.18632/oncotarget.12077 |
| PMID: | 27650547 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.12077 |